Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” a recent article reads. “Aditxt’s first commercial product is an immune monitoring technology trademarked as AditxtScore(TM) for COVID-19, which is designed to provide users with a personalized profile of their immune status – specifically in relation to their vulnerability and immune response regarding COVID’s SARS-CoV-2 virus and its known variants. The immune system profile gives patients and their medical providers data regarding COVID they can use to develop informed health decisions, and the technology is supported by the company’s AditxtScore(TM) immune monitoring center in Richmond, Virginia.”
To view the full article, visit https://ibn.fm/FnkXd
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork